Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.57 |
| ▸ | HPGDS | O60760 | 7/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20173756 | 0.88 | MGAM (0.57) | MGAMEGLN1EIF4A3SMN1; SMN2RXRA | |
| SCHEMBL22672566 | 0.81 | SMN1; SMN2 (0.48) | MGAMHPGDSEGLN1SMN1; SMN2RXRA | |
| SCHEMBL1285185 | 0.80 | MAOB (0.59) | HPGDSSMN1; SMN2OGA | |
| SCHEMBL69368 | 0.80 | MGAM (0.68) | MGAMHPGDSSMN1; SMN2GABRA1PSMD14 | |
| SCHEMBL10473057 | 0.79 | MGAM (0.62) | MGAMHPGDSSMN1; SMN2PSMD14 | |
| SCHEMBL11322091 | 0.78 | OGA (0.40) | HPGDSEIF4A3SMN1; SMN2OGA | |
| SCHEMBL24453564 | 0.77 | ESR2 (0.42) | HPGDSEIF4A3SMN1; SMN2OGA | |
| SCHEMBL1353291 | 0.77 | MGAM (0.64) | MGAMHPGDSPSMD14 | |
| SCHEMBL27970954 | 0.76 | RXRA (0.62) | MGAMEGLN1RXRARXRBRXRG | |
| SCHEMBL8081677 | 0.76 | KDM4E (0.55) | EIF4A3SMN1; SMN2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024272-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2024272-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | MGAM 4656/4885HPGDS 427/4885EGLN1 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.